New research suggests that people who discontinue popular GLP-1 drugs like Wegovy and Mounjaro tend to recover lost weight at a significantly accelerated pace than those who stop traditional lifestyle regimens.
Research printed in a major medical journal shows that while overweight individuals can lose substantial amounts of their body weight while on the medication, the mass comes back at an estimated rate of nearly a kilo each month after stopping.
"People purchasing these medications need to be aware of the risk of quick rebound weight gain when the medication ends," stated expert Dr. Susan Jebb.
This pace of recovery suggests a reversion to pre-treatment weight within about a year and a half.
Weighing Therapies
The analysis, which looked at 37 of trials involving thousands of patients, contrasted the results of GLP-1 agonists with older methods.
The team emphasize that individuals who lose weight through diet and exercise generally see a less rapid weight regain—around 100 grams monthly—after stopping.
Explaining the Quick Rebound
Nutrition scientists suggest the way of the injections is key to understanding the heightened weight return.
These medications imitate a body's own chemical called GLP-1, which moderates feelings of fullness.
"Artificially providing the hormone levels several times higher than normal might result in the body to generate a reduced amount of its own natural hormone, and may also reduce sensitivity to its effects," explained Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this medication means hunger is unsuppressed, making binge eating a significant risk."
An Ongoing Disease?
The NHS advise the jabs for people with weight-linked health risks, accompanied by recommended lifestyle changes.
Professionals contend that, given the high risk of relapse, the therapy should be considered long-term.
This opinion is reinforced by drug manufacturers, who note that the results "highlight the chronic nature of obesity," akin to managing conditions like hypertension.
User Experiences
Individuals who have stopped the medication explain a intense resurgence of cravings.
"I experienced a trigger activating and you become ravenous," recalled one woman.
This difficulty is compounded if users have not adopted sustainable dietary or behavioural modifications during treatment.
Growing Adoption
Figures show that millions of people in the UK have tried these injections in the last 12 months, with desire remaining high.
- Use is greater among women compared to men.
- The 40s and 50s age group shows the greatest level of interest.
- Many access the medications through private healthcare rather than public health services.
Ultimately, researchers emphasize that while GLP-1 drugs are potent agents for weight loss, they are not a permanent cure and maintained weight loss relies on combined behavioural management.
